Deslorelin vs Ipamorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileIpamorelin
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It stimulates GH release with high selectivity — minimal cortisol or prolactin elevation compared to older GHRPs. Widely used in research protocols for body composition, sleep quality, and recovery.
Full profile| Deslorelin | Ipamorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | NNC 26-0161, Ipamorelin acetate |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 100mcg–300mcg mcg, 1–3x daily (typically pre-sleep and/or pre-workout) |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Water retention (mild), Tingling / numbness in extremities, Increased appetite, Headache (transient) |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: Deslorelin is research-stage, while Ipamorelin is investigational (in trials).
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; Ipamorelin — Subcutaneous injection, Intramuscular injection.
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; Ipamorelin is 1–3x daily (typically pre-sleep and/or pre-workout).
- Research depth: this profile cites 2 sources for Deslorelin vs 3 for Ipamorelin.
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
Ipamorelin
Ipamorelin selectively stimulates GH release via the ghrelin receptor (GHS-R1a) without significantly elevating ACTH or cortisol — the feature that distinguishes it from GHRP-6 and GHRP-2 (Raun et al., 1998, in swine/rodent models). Human data are limited: a PK study in 40 volunteers established a ~2-hour half-life (Gobburu et al., 1999), and a Phase 2 trial for postoperative ileus (Beck et al., 2014) failed its primary endpoint. It is not FDA-approved, and claims about body composition or recovery are extrapolated from GH physiology, not human outcome trials.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.